Loading...

We've got a brand new version of Simply Wall St! Try it out

Syngen Biotech

GTSM:8279
Snowflake Description

Flawless balance sheet with proven track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
8279
GTSM
NT$3B
Market Cap
  1. Home
  2. TW
  3. Pharmaceuticals & Biotech
Company description

Syngen Biotech Co., Ltd. operates as a biotech company in Taiwan. The last earnings update was 12 days ago. More info.


Add to Portfolio Compare Print
  • Syngen Biotech has significant price volatility in the past 3 months.
8279 Share Price and Events
7 Day Returns
-2.5%
GTSM:8279
-1.7%
TW Pharmaceuticals
-0.5%
TW Market
1 Year Returns
22.1%
GTSM:8279
16%
TW Pharmaceuticals
17.7%
TW Market
8279 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Syngen Biotech (8279) -2.5% -8.7% -15.8% 22.1% 6.3% 302.9%
TW Pharmaceuticals -1.7% 3.4% 3.5% 16% -10.7% -23.2%
TW Market -0.5% 2.8% 9.1% 17.7% 26.3% 26.1%
1 Year Return vs Industry and Market
  • 8279 outperformed the Pharmaceuticals industry which returned 16% over the past year.
  • 8279 outperformed the Market in Taiwan, Province of China which returned 17.7% over the past year.
Price Volatility
8279
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Syngen Biotech's competitors could be found in our database.

8279 Value

 Is Syngen Biotech undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Syngen Biotech to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Syngen Biotech.

GTSM:8279 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.7%
Perpetual Growth Rate 10-Year TW Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for GTSM:8279
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year TW Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.69
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.687 (1 + (1- 20%) (11.7%))
0.834
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.83
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.834 * 5.96%)
7.7%

Discounted Cash Flow Calculation for GTSM:8279 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Syngen Biotech is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

GTSM:8279 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (TWD, Millions) Source Present Value
Discounted (@ 7.7%)
2020 30.69 Est @ 51.52% 28.49
2021 42.01 Est @ 36.88% 36.22
2022 53.20 Est @ 26.64% 42.58
2023 63.55 Est @ 19.46% 47.24
2024 72.73 Est @ 14.44% 50.19
2025 80.68 Est @ 10.93% 51.70
2026 87.51 Est @ 8.47% 52.07
2027 93.42 Est @ 6.75% 51.61
2028 98.59 Est @ 5.54% 50.58
2029 103.23 Est @ 4.7% 49.17
Present value of next 10 years cash flows NT$459.00
GTSM:8279 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= NT$103.23 × (1 + 2.73%) ÷ (7.7% – 2.73%)
NT$2,134.18
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= NT$2,134.18 ÷ (1 + 7.7%)10
NT$1,016.53
GTSM:8279 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= NT$459.00 + NT$1,016.53
NT$1,475.53
Equity Value per Share
(TWD)
= Total value / Shares Outstanding
= NT$1,475.53 / 27.10
NT$54.45
GTSM:8279 Discount to Share Price
Calculation Result
Value per share (TWD) From above. NT$54.45
Current discount Discount to share price of NT$115.00
= -1 x (NT$115.00 - NT$54.45) / NT$54.45
-111.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Syngen Biotech is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Syngen Biotech's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Syngen Biotech's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
GTSM:8279 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in TWD NT$7.85
GTSM:8279 Share Price ** GTSM (2019-11-15) in TWD NT$115
Taiwan, Province of China Pharmaceuticals Industry PE Ratio Median Figure of 26 Publicly-Listed Pharmaceuticals Companies 22.23x
Taiwan, Province of China Market PE Ratio Median Figure of 1,423 Publicly-Listed Companies 16.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Syngen Biotech.

GTSM:8279 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= GTSM:8279 Share Price ÷ EPS (both in TWD)

= 115 ÷ 7.85

14.65x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Syngen Biotech is good value based on earnings compared to the TW Pharmaceuticals industry average.
  • Syngen Biotech is good value based on earnings compared to the Taiwan, Province of China market.
Price based on expected Growth
Does Syngen Biotech's expected growth come at a high price?
Raw Data
GTSM:8279 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 14.65x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Taiwan, Province of China Pharmaceuticals Industry PEG Ratio Median Figure of 5 Publicly-Listed Pharmaceuticals Companies 0.89x
Taiwan, Province of China Market PEG Ratio Median Figure of 247 Publicly-Listed Companies 1.07x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Syngen Biotech, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Syngen Biotech's assets?
Raw Data
GTSM:8279 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in TWD NT$51.71
GTSM:8279 Share Price * GTSM (2019-11-15) in TWD NT$115
Taiwan, Province of China Pharmaceuticals Industry PB Ratio Median Figure of 45 Publicly-Listed Pharmaceuticals Companies 2.17x
Taiwan, Province of China Market PB Ratio Median Figure of 1,936 Publicly-Listed Companies 1.44x
GTSM:8279 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= GTSM:8279 Share Price ÷ Book Value per Share (both in TWD)

= 115 ÷ 51.71

2.22x

* Primary Listing of Syngen Biotech.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Syngen Biotech is overvalued based on assets compared to the TW Pharmaceuticals industry average.
X
Value checks
We assess Syngen Biotech's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Syngen Biotech has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

8279 Future Performance

 How is Syngen Biotech expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
32.3%
Expected annual growth in earnings per share.
Earnings growth vs Low Risk Savings
Is Syngen Biotech expected to grow at an attractive rate?
  • Syngen Biotech's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Syngen Biotech's earnings growth is expected to exceed the Taiwan, Province of China market average.
  • Unable to compare Syngen Biotech's revenue growth to the Taiwan, Province of China market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
GTSM:8279 Future Growth Rates Data Sources
Data Point Source Value (per year)
GTSM:8279 Future Earnings per Share Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 32.3%
Taiwan, Province of China Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 11.8%
Taiwan, Province of China Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 20.2%
Taiwan, Province of China Market Earnings Growth Rate Market Cap Weighted Average 11.4%
Taiwan, Province of China Market Revenue Growth Rate Market Cap Weighted Average 8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
GTSM:8279 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in TWD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
GTSM:8279 Future Estimates Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31
2019-12-31 1,385 139 197 1
2019-11-18
GTSM:8279 Past Financials Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income *
2019-09-30 1,281 211 181
2019-06-30 1,242 171 184
2019-03-31 1,152 129 153
2018-12-31 1,080 67 134
2018-09-30 997 74 116
2018-06-30 959 89 126
2018-03-31 944 197 143
2017-12-31 956 161 149
2017-09-30 934 90 145
2017-06-30 872 86 117
2017-03-31 809 41 96
2016-12-31 769 47 90

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Syngen Biotech's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Syngen Biotech is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
GTSM:8279 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Syngen Biotech Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:8279 Future Estimates Data
Date (Data in TWD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31 11.88 11.88 11.88 1.00
2019-12-31 9.06 9.06 9.06 1.00
2019-11-18
GTSM:8279 Past Financials Data
Date (Data in TWD Millions) EPS *
2019-09-30 7.85
2019-06-30 7.96
2019-03-31 6.61
2018-12-31 5.80
2018-09-30 5.04
2018-06-30 5.47
2018-03-31 6.19
2017-12-31 6.43
2017-09-30 6.27
2017-06-30 5.19
2017-03-31 4.41
2016-12-31 4.26

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Syngen Biotech will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Syngen Biotech's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Taiwan, Province of China market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Taiwan, Province of China market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Syngen Biotech has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

8279 Past Performance

  How has Syngen Biotech performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Syngen Biotech's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Syngen Biotech has delivered over 20% year on year earnings growth in the past 5 years.
  • Syngen Biotech's 1-year earnings growth exceeds its 5-year average (55.7% vs 28.7%)
  • Syngen Biotech's earnings growth has exceeded the TW Pharmaceuticals industry average in the past year (55.7% vs 12.7%).
Earnings and Revenue History
Syngen Biotech's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Syngen Biotech Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:8279 Past Revenue, Cash Flow and Net Income Data
Date (Data in TWD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 1,280.58 181.33 193.21 53.59
2019-06-30 1,242.24 183.85 180.59 50.98
2019-03-31 1,152.02 152.77 166.68 49.53
2018-12-31 1,080.45 133.99 165.58 45.66
2018-09-30 996.81 116.45 158.09 43.95
2018-06-30 959.10 126.44 150.59 40.86
2018-03-31 943.77 143.10 145.87 39.73
2017-12-31 955.65 148.62 143.86 39.87
2017-09-30 934.38 144.89 136.13 39.96
2017-06-30 871.70 116.85 133.26 42.00
2017-03-31 809.39 96.19 131.57 42.18
2016-12-31 769.37 90.21 124.62 42.91
2016-09-30 730.51 79.22 118.43 49.37
2016-06-30 673.23 67.64 109.54 47.16
2016-03-31 639.41 65.02 101.09 46.74
2015-12-31 644.46 66.96 96.83 46.02
2015-09-30 625.85 66.73 97.76 40.31
2015-06-30 625.90 59.29 99.86 42.27
2015-03-31 599.63 44.62 99.59 44.06
2014-12-31 555.90 34.77 99.35 46.25
2014-09-30 475.61 21.97 92.15 50.28
2014-06-30 395.32 9.17 84.95 54.32
2014-03-31 335.40 11.92 77.53 49.63
2013-12-31 275.47 14.68 70.11 44.95
2012-12-31 203.08 16.84 46.23 20.16

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Syngen Biotech has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Syngen Biotech used its assets more efficiently than the TW Pharmaceuticals industry average last year based on Return on Assets.
  • Syngen Biotech's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Syngen Biotech's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Syngen Biotech has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

8279 Health

 How is Syngen Biotech's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Syngen Biotech's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Syngen Biotech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Syngen Biotech's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Syngen Biotech's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 4.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Syngen Biotech Company Filings, last reported 1 month ago.

GTSM:8279 Past Debt and Equity Data
Date (Data in TWD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 1,192.44 208.49 434.69
2019-06-30 908.14 109.80 110.77
2019-03-31 907.07 151.06 196.49
2018-12-31 873.14 167.31 128.55
2018-09-30 830.22 163.56 100.64
2018-06-30 782.32 154.81 92.50
2018-03-31 775.53 126.06 134.46
2017-12-31 764.00 167.30 171.16
2017-09-30 739.14 168.53 141.96
2017-06-30 681.16 139.76 128.62
2017-03-31 657.68 140.97 154.49
2016-12-31 637.28 22.67 249.41
2016-09-30 615.29 28.37 229.11
2016-06-30 430.42 31.86 49.21
2016-03-31 415.91 132.83 52.64
2015-12-31 401.49 236.43 54.46
2015-09-30
2015-06-30 373.12 109.49 121.31
2015-03-31 286.80 129.71 61.83
2014-12-31 286.80 129.71 61.83
2014-09-30 286.80 129.71 61.83
2014-06-30 270.29 132.18 40.35
2014-03-31 270.29 132.18 40.35
2013-12-31 250.66 107.37 101.13
2012-12-31 242.00 81.32 66.73
  • Syngen Biotech's level of debt (17.5%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (45.2% vs 17.5% today).
  • Debt is well covered by operating cash flow (101.3%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 69.2x coverage).
X
Financial health checks
We assess Syngen Biotech's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Syngen Biotech has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

8279 Dividends

 What is Syngen Biotech's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
2.17%
Current annual income from Syngen Biotech dividends.
If you bought NT$2,000 of Syngen Biotech shares you are expected to receive NT$43 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Syngen Biotech's pays a lower dividend yield than the bottom 25% of dividend payers in Taiwan, Province of China (2.57%).
  • Syngen Biotech's dividend is below the markets top 25% of dividend payers in Taiwan, Province of China (5.93%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
GTSM:8279 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Taiwan, Province of China Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 23 Stocks 2.8%
Taiwan, Province of China Market Average Dividend Yield Market Cap Weighted Average of 1323 Stocks 4.1%
Taiwan, Province of China Minimum Threshold Dividend Yield 10th Percentile 1.4%
Taiwan, Province of China Bottom 25% Dividend Yield 25th Percentile 2.6%
Taiwan, Province of China Top 25% Dividend Yield 75th Percentile 5.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

GTSM:8279 Future Dividends Estimate Data
Date (Data in NT$) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2019-12-31
2019-11-18
GTSM:8279 Past Annualized Dividends Data
Date (Data in NT$) Dividend per share (annual) Avg. Yield (%)
2019-03-26 2.500 1.929
2018-03-28 0.909 0.835
2017-03-31 0.909 0.794
2016-03-25 0.455 0.604

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, Syngen Biotech has been paying a dividend for less than 10 years.
  • Dividend payments have increased, but Syngen Biotech only paid a dividend in the past 4 years.
Current Payout to shareholders
What portion of Syngen Biotech's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (3.1x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Syngen Biotech's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Syngen Biotech afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Syngen Biotech has a total score of 1/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

8279 Management

 What is the CEO of Syngen Biotech's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Wei Ren Chen
TENURE AS CEO 14.3 years
CEO Bio

Wei Ren Chen has been Chairman of the Board and President of Syngen Biotech Co., Ltd. since March 15, 1999 and July 1, 2005 respectively. Wei Ren Chen is employed by Taiwan Drug Relief Foundation. Wei Ren Chen serves as Deputy President at Standard Chem. & Pharm. Co., Ltd. Wei Ren Chen serves as Chairman of the Board at Taiwan Generic Pharmaceutical Association. Wei Ren Chen serves as Director of Taiwan Drug Relief Foundation. Wei Ren Chen serves as an Executive director of Chinese Pharmaceutical Manufacture and Development Association. Wei Ren Chen serves as Director of Souriree Biotech Pharmaceutical Co., Ltd. Wei Ren Chen serves as Director of Multipower Enterprise Co., Ltd. Wei Ren Chen serves as Director of We Can Medicines Co., Ltd. Wei Ren Chen serves as Director of Jiangsu Sheng Dasheng Technology Pharmaceutical Co., Ltd Wei Ren Chen holds Master of senior management from Southern Taiwan University of Science and Technology.

CEO Compensation
  • Insufficient data for Wei Ren to compare compensation growth.
  • Insufficient data for Wei Ren to establish whether their remuneration is reasonable compared to companies of similar size in Taiwan, Province of China.
Management Team

Wei Ren Chen

TITLE
Chairman of the Board and President
TENURE
14.3 yrs

Zhi Ming Huang

TITLE
Finance Manager and Director
TENURE
19.3 yrs
Board of Directors Tenure

Average tenure of the Syngen Biotech board of directors in years:

6.4
Average Tenure
  • The tenure for the Syngen Biotech board of directors is about average.
Board of Directors

Wei Ren Chen

TITLE
Chairman of the Board and President
TENURE
20.7 yrs

Zhi Ming Huang

TITLE
Finance Manager and Director
TENURE
6.4 yrs

Jin Cai Fan

TITLE
Director
TENURE
6.4 yrs

Zi Ting Fan

TITLE
Director
TENURE
6.4 yrs

San Fa Wu

TITLE
Director
TENURE
6.4 yrs

Rong Zhan Xie

TITLE
Supervisor
TENURE
6.4 yrs

Cui Ye

TITLE
Supervisor
TENURE
6.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (NT$) Value (NT$)
X
Management checks
We assess Syngen Biotech's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Syngen Biotech has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

8279 News

Simply Wall St News

8279 Company Info

Description

Syngen Biotech Co., Ltd. operates as a biotech company in Taiwan. The company manufactures and sells active pharmaceutical ingredients, including Mupirocin, an antibiotic against gram-positive bacteria that is used for the topical treatment of superficial infections; and nutraceutical ingredients comprising probiotics, medicinal fungi, and entomogenous fungi. It also offers biology fermentation products, biology agriculture and aquaculture products, and functional food products. The company was founded in 1999 and is based in Tainan City, Taiwan.

Details
Name: Syngen Biotech Co., Ltd.
8279
Exchange: GTSM
Founded: 1999
NT$3,116,597,865
27,100,851
Website: http://www.syngen.com.tw
Address: Syngen Biotech Co., Ltd.
No.154, Kaiyuan Road,
Sinying District,
Tainan City,
73055,
Taiwan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
GTSM 8279 Common Stock Taipei Exchange TW TWD 15. Apr 2004
Number of employees
Current staff
Staff numbers
0
Syngen Biotech employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 14:32
End of day share price update: 2019/11/15 00:00
Last estimates confirmation: 2019/10/18
Last earnings filing: 2019/11/06
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.